All In Biotech

Drug Trial Radar · NCT02215265

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,269 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,269

Planned (sponsor's estimate)

Start

Oct 2015

Primary completion

Oct 2027

Study completion Apr 2028

Sponsor

Lead sponsor
Lisette NixonGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
UNICANCER; AdventHealth; University of Leipzig; Princess Alexandra Hospital, Brisbane, Australia; Stanford University
First posted
Aug 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment arms.

Conditions

  • Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

Interventions

  • CisplatinDrug

    Chemotherapy

  • Postoperative radiotherapyRadiation

    Postoperative radiotherapy (PORT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MDADI/Overall survival co-primary endpointTime frame: At 12 months following treatment measured using the MD Anderson Dysphagia Inventory (MDADI) score.

Locations

57 sites in 5 countries. Site status is shown where the registry gives one.

  • Board of Trustees of the Leland Stanford Junior University

    Redwood City, California

  • Advent Health

    Orlando, Florida

  • MD Anderson Cancer Centre

    Houston, Texas

  • Metro South Health

    Brisbane, Australia

  • Unicancer

    Paris, France

  • Vivantes Klinikum

    Berlin, Germany

  • Zentrum für Hals-, Nasen- und Ohrenheilkunde

    Giessen, Germany

  • Asklepios Kliniken

    Hamburg, Germany

  • Kath Marienkrankenhaus gGmbH

    Hamburg, Germany

  • Universitaetsklinikum des Saarlandes

    Homburg, Germany

  • Universitat Leipzig

    Leipzig, Germany

  • Ernst von Bergmann Klinikum

    Potsdam, Germany

  • Städtisches Klinikum Solingen

    Solingen, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Royal United Hospitals Bath NHS Foundation Trust

    Bath, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Royal Blackburn Hospital

    Blackburn, United Kingdom

  • Royal Sussex County Hospital

    Brighton, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust

    Bristol, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Kent and Canterbury Hospital

    Canterbury, United Kingdom

  • HPV Research Group Section of Pathology Cardiff University ,School of Medicine

    Cardiff, United Kingdom

  • Cardiff and Vale University Local Health Board

    Cardiff, United Kingdom

  • Centre for Trials Research

    Cardiff, United Kingdom

  • Velindre NHS Trust

    Cardiff, United Kingdom

  • Castle Hill Hospital

    Cottingham, United Kingdom

  • Derby Teaching Hospitals NHS Foundation Trust

    Derby, United Kingdom

  • Western General Hospital

    Edinburgh, United Kingdom

  • Royal Devon University Health Care NHS Foundation Trust

    Exeter, United Kingdom

  • Royal Surrey County Hospital

    Guildford, United Kingdom

  • St James University Hospital

    Leeds, United Kingdom

  • Liverpool Head and Neck Centre

    Liverpool, United Kingdom

  • University of Liverpool

    Liverpool, United Kingdom

  • Cwm Taf Bro Morganwg

    Llantrisant, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Guys and St Thomas's NHS Foundation Trust

    London, United Kingdom

  • St Georges University Hospital

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Central Manchester University Hospital NHS Foundation Trust

    Manchester, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.